Millipore Sigma Vibrant Logo

204906 Complement C5b,6 Complex, Human

Complement C5b,6 Complex, Human, is a native complement complex where the nascent C5b fragment is combined with C6 to form a stable complex.

Complement C5b,6 Complex, Human: Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.
View Products on Sigmaaldrich.com
204906
Ver precios y disponibilidad

Descripción

Replacement Information

Precios y disponibilidad

Número de referencia DisponiblidadEmbalaje Cant./Env. Precio Cantidad
204906-50UG
Comprobando disponibilidad...
—
Disponibilidad a confirmar Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

      		 Ampolla de plást. 50 μg
      Recuperando precio...
      No pudo obtenerse el precio
      La cantidad mínima tiene que ser múltiplo de
      Maximum Quantity is
      Al finalizar el pedido Más información
      Ahorró ()
       
      —
      Solicitar precio
      		 —
      Description
      OverviewNative, human C5b,6 complement component complex. Activation of complement by either pathway results in the formation of C5-cleaving enzymes (C5 convertases) on target surfaces. The C5 convertase enzymes cleave the C5 α-chain at peptide bond 74, resulting in the formation of the C5a anaphylatoxin (M.W. 11,200) and the C5b fragment (M.W. 185,000). The nascent C5b fragment can combine with C6, C7, C8, and C9 to form the lytic C5b-9 membrane attack complex on target surfaces. When C5 activation occurs in the presence of C6 only, e.g. in C7 deficient serum, a stable C5b,6 complex is formed. In a process termed Reactive Lysis, the membrane attack complex can be assembled on target cell surfaces in the absence of any additional complement proteins by incubating target cells with the C5b,6 complex and purified C7, C8, and C9.
      Catalogue Number204906
      Brand Family Calbiochem®
      References
      ReferencesPodack, E.R., et al. 1978. J. Immunol. 120, 1841.
      Lachmann, P.J. and Thompson, R.A. 1970. J. Exp. Med. 131, 643.
      Product Information
      FormLiquid
      FormulationIn 120 mM NaCl, 10 mM HEPES, pH 7.2.
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥95% by SDS-PAGE
      SourcePrepared from plasma of individuals that have been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
      Specific Activity≥2000 C5b,6H50 units/mg
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Standard Handling
      Storage ≤ -70°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      204906-50UG 04055977219883

      Documentation

      Complement C5b,6 Complex, Human Ficha datos de seguridad (MSDS)

      Título

      Ficha técnica de seguridad del material (MSDS) 

      Complement C5b,6 Complex, Human Certificados de análisis

      CargoNúmero de lote
      204906

      Referencias bibliográficas

      Visión general referencias
      Podack, E.R., et al. 1978. J. Immunol. 120, 1841.
      Lachmann, P.J. and Thompson, R.A. 1970. J. Exp. Med. 131, 643.
      Ficha técnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision27-May-2008 RFH
      DescriptionNative, human C5b,6 complement component complex. Activation of complement by either pathway results in the formation of C5-cleaving enzymes (C5 convertases) on target surfaces. The C5 convertase enzymes cleave the C5 α-chain at peptide bond 74, resulting in the formation of the C5a anaphylatoxin (M.W. 11,200) and the C5b fragment (M.W. 185,000). The nascent C5b fragment can combine with C6, C7, C8 and C9 to from the lytic C5b-9 membrane attack complex on target surfaces. When C5 activation occurs in the presence of C6 only, e.g. in C7 deficient serum, a stable C5b,6 complex is formed. In a process termed Reactive Lysis, the membrane attack complex can be assembled on target cell surfaces in the absence of any additional complement proteins by incubating target cells with the C5b,6 complex and purified C7, C8 and C9.
      FormLiquid
      FormulationIn 120 mM NaCl, 10 mM HEPES, pH 7.2.
      Concentration Label Please refer to vial label for lot-specific concentration
      SourcePrepared from plasma of individuals that have been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
      Purity≥95% by SDS-PAGE
      Specific activity≥2000 C5b,6H50 units/mg
      Storage Avoid freeze/thaw
      ≤ -70°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Toxicity Standard Handling
      ReferencesPodack, E.R., et al. 1978. J. Immunol. 120, 1841.
      Lachmann, P.J. and Thompson, R.A. 1970. J. Exp. Med. 131, 643.